One Inhaler Rewrites Severe Asthma Care

Person holding an asthma inhaler — Photo: Orawan Pattarawimonchai / Shutterstock

One inhaler can now do the job that used to take two, and national guidelines say that change is backed by real evidence for the right patients.

Quick Take

National guidelines support using a single inhaler with a steroid and formoterol for both daily control and quick relief of asthma symptoms.
The approach, often called SMART, is a preferred option for moderate to severe persistent asthma in patients age four and older.
Dosing limits exist to keep the strategy safe, with stricter caps for children than for teens and adults.
International guidelines use different names for similar strategies, which can confuse patients comparing advice across sources.

What The Recommendation Actually Says

Johns Hopkins Medicine recently highlighted a treatment approach that combines an inhaled corticosteroid with formoterol in one inhaler. Patients use it every day as a controller and again when symptoms flare. This mirrors official U.S. guidance. The National Institutes of Health’s lung institute recommends this exact combination as both “daily controller and quick-relief therapy” for appropriate patients.

The strategy carries a formal name: single maintenance and reliever therapy, or SMART. It is not a fringe idea. The 2020 update to the national asthma guidelines names ICS-formoterol combinations as the preferred Step 3 and Step 4 treatment for people four and older with moderate to severe persistent asthma, replacing the older model of a separate daily inhaler and a separate rescue inhaler.

Why One Inhaler Can Handle Two Jobs

Asthma flares happen for two reasons. The airways tighten, and they swell with inflammation. Older rescue inhalers only addressed the tightening. Formoterol relaxes airway muscles fast, while the steroid calms inflammation at the source. Combining them lets one device treat both problems at once, whether a patient uses it on schedule or reaches for it during a bad moment.

Guideline writers did not take this approach lightly. The National Institutes of Health’s asthma panel reviewed the evidence and gave single-inhaler therapy a strong recommendation for many patients, while noting some specific comparisons still lack enough data. That mix of confidence and honesty is exactly what families should want from medical guidance.

Children Are Included, Within Limits

This is not just an adult strategy. The guidelines include a preferred recommendation for children ages five to eleven at Steps 3 and 4, and the Global Initiative for Asthma lists similar options for children six to eleven. That said, age alone does not qualify a child. Severity and treatment step matter too, and the guidelines are specific about which kids fit the recommendation.

Safety rails come built in. Children ages four to eleven should not exceed eight inhalations a day, while patients twelve and older cap out at twelve. Crossing those limits is a signal to call a doctor, not to keep dosing. Those numbers give parents a clear, concrete benchmark instead of vague reassurance.

Where Confusion Still Creeps In

Terminology trips people up. American guidelines call this SMART. International guidelines often say MART or describe it as an “anti-inflammatory reliever.” Different labels for a similar idea can make the same treatment look like competing advice, especially when patients compare notes from different doctors or countries.

Not every combination inhaler qualifies for this use, either. The guidelines are specific about the ICS-formoterol class and its dosing, not a blanket rule that any steroid-and-bronchodilator inhaler works the same way. Patients should confirm with their own doctor which product and dose fits their prescription before assuming they qualify.

The Bigger Picture For Families Managing Asthma

Medication is one piece of a larger plan. The guidelines frame drug choice alongside trigger avoidance, correct inhaler technique, and regular reassessment by a doctor. A simplified inhaler routine helps, but it works best paired with an asthma action plan and follow-up visits, not as a standalone fix parents set and forget.

Cost and access also shape how this plays out in real homes. Insurance rules, refill limits, and product availability can affect whether a family can actually follow the regimen a guideline recommends. The clinical case for single-inhaler therapy is strong, but turning that case into daily practice still depends on what a pharmacy counter and an insurance plan allow.